Ozmosi | Propagermanium Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Propagermanium

Alternative Names: propagermanium, dmx-200, dmx200, dmx 200
Clinical Status: Active
Latest Update: 2025-12-19
Latest Update Note: News Article

Product Description

Mechanisms of Action: CCR2 Inhibitor, ARB Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dimerix Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Propagermanium

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 6

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: COVID-19|Glomerulosclerosis, Focal Segmental|Influenza, Human|Kidney Diseases|Pneumonia

Phase 1: Proteinuria

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12617001640392

 ACTRN12617001640392

P1

Active, not recruiting

Kidney Diseases|Proteinuria

2017-11-24

2024-08-29

Treatments

ACTRN12622000066785

 ACTION3

P3

Recruiting

Glomerulosclerosis, Focal Segmental|Kidney Diseases

2026-03-31

2025-12-06

Patient Enrollment|Primary Completion Date|Treatments

NCT02735707

 REMAP-CAP

P3

Recruiting

COVID-19|Influenza, Human|Pneumonia

2026-02-01

2024-11-27

jRCT2031250150

 jRCT2031250150

P3

Not yet recruiting

Glomerulosclerosis, Focal Segmental

2030-02-28

NCT05183646

 ACTION3

P3

Recruiting

Kidney Diseases|Glomerulosclerosis, Focal Segmental

2029-12-01

23%

2025-08-27

Primary Endpoints|Treatments

2023-504597-37-00

 DMX-200-301

P3

Recruiting

Glomerulosclerosis, Focal Segmental

2026-11-30

2025-05-02

Treatments

Recent News Events

Date

Type

Title

12/19/2025

News Article

 BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

06/10/2025

News Article

 New Spherix Global Insights Data Reveals 85% of FSGS Patients Have Actively Progressing Disease Despite Treatment, Underscoring Urgent Demand for Innovative Treatments

04/30/2025

News Article

 Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

11/01/2024

News Article

 Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs

05/04/2024

PubMed

 Investigation of Strategies to Block Downstream Effectors of AT1R-Mediated Signalling to Prevent Aneurysm Formation in Marfan Syndrome.

04/11/2023

PubMed

 Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.

04/01/2023

PubMed

 GM-CSF-producing CCR2+ CCR6+ Th17 cells are pathogenic in dextran sodium sulfate-induced colitis model in mice.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions